Form D · Other

Affinia Therapeutics Inc.

Waltham, MA · CIK 0001792694

Offering snapshot reported Oct 14, 2025 · SEC filing

Reported sold
$13.3M
Offering amount: $45M
Investors reported
20
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 16, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 14, 2025Initial$13,268,335No comparison20SEC filing
May 6, 2021Initial$109,999,955No comparisonNot reportedSEC filing
Mar 27, 2020Initial$38,522,942No comparison16SEC filing
Nov 5, 2019Initial$8,350,000No comparison14SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-560739

Source: Form D, filed Oct 14, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Aboud Executive
Charles Albright Executive
Diana Brainard Director
Paula Cobb Executive
Rami Daoud Executive
Carole Faig Director
David Grayzel Director
Robert Johnson Executive
Petra Kaufmann Executive
Edward Mathers Director
Rob May Executive
Rick Modi Director, Executive
Sean Nolan Director
Laura Richman Executive
Elliot Sigal Director
Elliott Sigal Director
Caroline Stout Director
Luc Vandenberghe Director
Luk Vandenberghe Director
Robert Weisskoff Director

Issuer details

Industry: Other (See others in industry)

Address:
43 Foundry Ave, Suite 120
Waltham, MA, 02453